Quali Streamlines Delivery of Agentic AI at Scale with NVIDIA AI Enterprise
AUSTIN, Texas, March 18, 2025 (GLOBE NEWSWIRE) -- Quali, a leading provider of platform engineering solutions for infrastructure automation and management, today announced its integration with NVIDIA AI Enterprise software, including NVIDIA NIM™ microservices and NVIDIA AI Blueprints, to simplify the creation and management of Agentic AI solutions.
Agentic AI represents a transformational opportunity for today's enterprises, with implications across internal operations and customer experience.
By leveraging NVIDIA NIM microservices and NVIDIA AI Blueprints included in the NVIDIA AI Enterprise software platform, the Quali Torque Software-as-a-Service platform simplifies the orchestration and management of each layer of the Agentic AI tech stack: accelerated infrastructure, cloud services and data pipelines, LLMs and AI models, and AI agents and applications.
With Torque providing unified orchestration, lifecycle management, and cost optimization, each layer of the development stack seamlessly supports each other to ensure reliability, accuracy, and efficiency.
To accomplish this, Torque manages the entire infrastructure lifecycle using Environments as Code (EaC)—a model that transforms cloud resources into fully managed, self-service environments supporting mission-critical operations, such as AI workloads, software development, demos, training, and more.
Quali can deploy and manage the entire tech stack supporting Agentic AI solutions as a stateful, dynamic environment through the integration of NVIDIA technology. This approach cuts through complexity and automates routine tasks, enabling more organizations to adopt Agentic AI faster, scale more efficiently, and focus on innovation rather than infrastructure management.
Key highlights of this release include:
Easy-to-Use Modules of NVIDIA AI Enterprise & Other NVIDIA Resources: Torque creates reusable modules defining each component needed to deliver an AI agent, including NVIDIA accelerated compute, NVIDIA NIM microservices, and pre-trained models and data science frameworks included with NVIDIA AI Enterprise. This normalization enables no-code orchestration of each layer of the stack supporting the AI solution, thereby accelerating delivery and lowering the barrier to adoption of Agentic AI.
AI-Driven Environment Design, Creation, & Reusability: Torque's AI Copilot leverages these reusable modules to design and generate new environment blueprints in response to user-submitted prompts. Additionally, Torque's graphical environment design tool allows users to drag-and-drop resources and set dependencies visually. As the user adjusts the design of the environment, Torque modifies the code in the environment blueprint file automatically, further reducing the need for complex coding to support the AI solution. Once complete, Torque saves this blueprint as a reusable file that can be deployed, maintained, and monitored continuously.
Simplified Provisioning & Maintenance of Individual Layers of the Agentic AI Tech Stack: Torque executes the code to provision each layer of the AI tech stack, monitors the state of those resources continuously, and notifies users about anomalies, including infrastructure errors, configuration drift, and other unexpected updates. This allows Torque administrators to tailor the user experience to the people responsible for delivering each layer of the AI tech stack, enabling them to reconcile errors and other unexpected issues proactively.
Streamlined Integration of Each Layer of the AI Tech Stack: Once provisioned as a managed environment in Torque, each layer of the AI tech stack can be published so other users can access it as an input supporting other layers of the stack. For example, a developer building an AI agent can select the live GPU clusters, cloud-based data services, and AI models they need from a simple pick list made available in Torque's provisioning experience. Torque leverages those inputs to provision the AI agent, while also enabling users to maintain the live environment supporting each layer of the stack. This provides a seamless experience that cuts through complexity and accelerates the delivery of full-stack AI agents.
Automating Critical Tasks for AI Performance: Torque workflows can define and automatically execute routine tasks required to maintain high-performing AI solutions, such as training and data quality assurance. This eliminates manual work required for day-to-day maintenance, while also providing visibility for users to understand when these tasks were last executed, how effective they were, and other relevant information.
Dynamic GPU Scaling in Response to Application Needs: As the various AI models supporting the agent transition through mission-critical phases, Torque automatically scales GPUs up and down. This provides adequate computing capacity to support even the most resource-intensive workloads like training, while scaling down capacity to prevent costly over-provisioning for less resource-intensive tasks like inference.
'Complexity has always been at the core of the problems we solve for our customers and partners,' said Lior Koriat, Quali CEO. 'As more organizations look to embrace AI, the ability to cut through complexity is the key to delivering the kinds of AI experiences that customers expect. We're thrilled to develop a streamlined approach for delivering impactful AI solutions leveraging NVIDIA AI, and we look forward to helping our community unlock these opportunities.'
About Quali:
Headquartered in Austin, Texas, Quali provides platform engineering tools to help enterprise technology and engineering teams accelerate and optimize the use of multi-cloud infrastructure. Global 2000 enterprises rely on Quali's solutions to democratize cloud access securely and efficiently by simplifying the experience of deploying application environments and enforcing cloud governance at scale. For more information, please visit quali.com and follow Quali on LinkedIn.
Contact Information:
Colin Neagle VP of Marketing Quali Colin.n@quali.com www.quali.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
15 minutes ago
- CNBC
Nvidia says its AI chips do not have a 'kill switch' after Chinese accusation
Nvidia on Tuesday rejected Chinese accusations that its data center GPUs for artificial intelligence include a hardware function that could remotely deactivate the chips, which is commonly called a "kill switch." "NVIDIA GPUs do not and should not have kill switches and backdoors," wrote Nvidia's Chief Security Officer David Reber in a blog post on Tuesday. The blog post comes after the Cyberspace Administration of China said last week that it needed Nvidia to provide documents about what it called security vulnerabilities in the H20, Nvidia's data center AI chip intended for the Chinese market. The regulator specifically mentioned "backdoor" security risks, according to the New York Times. The statement is an example of how Nvidia is navigating geopolitical conflict as its AI chips remain in high demand by countries and companies around the world. U.S. lawmakers have proposed legislation that would require AI chips under export regulations to be equipped with location-tracking systems. The U.S. has placed export controls on some Nvidia chips to China because of national security reasons, saying that the country could use the chips to gain an advantage in AI or for military purposes. Nvidia CEO Jensen Huang has argued that it is better for the U.S. if Nvidia's chips become the global standard for AI computers, especially among Chinese developers. The H20 generates billions in revenue per quarter for Nvidia in sales, although the company does not typically break out its revenue specifically. The chip was briefly banned from export to China in April. The company said its guidance would have been about $8 billion higher except for lost sales from a recent export restriction on its China-bound H20 chips. The Trump administration said in July that it would grant a waiver for the chips to resume sales. Silicon Valley technologists and security experts generally believe that backdoors — when a device has a hidden function that would allow a government or attacker to secretly take data from a computer or otherwise control it — are untenable in products. Apple, in particular, has publicly fought off government requests for what it calls "backdoors" in the past as well. Nvidia declined to comment further on its blog post. Reber argued in the blog post that secret backdoors are dangerous vulnerabilities that could be used by hackers, not just officials, and that they "violate the fundamental principles of cybersecurity." He also said that if a kill switch or backdoor were to be put in products like Nvidia GPUs, that they would harm U.S. national security interests. "Hardwiring a kill switch into a chip is something entirely different: a permanent flaw beyond user control, and an open invitation for disaster," Reber wrote. "It's like buying a car where the dealership keeps a remote control for the parking brake — just in case they decide you shouldn't be driving."
Yahoo
42 minutes ago
- Yahoo
Foxconn to sell former car factory in Ohio for $375m
Taiwan's Foxconn has finalised a deal to sell a former car factory in Lordstown, Ohio, for $375m, which includes the facility's machinery, according to a report by Reuters. Despite the sale, Foxconn plans to continue operations at the site, focusing on a broader range of products that align with its strategic priorities. The company, known for manufacturing data centre products for Nvidia and assembling iPhones for Apple, did not specify the exact products to be produced at the plant. However, it noted that its cloud and networking product business has experienced "significant growth." A source familiar with the situation informed Reuters that the Ohio facility is expected to support artificial intelligence (AI) data centres. The site spans over six million square feet, making it six times larger than a plant Foxconn is currently constructing in Houston for the production of Nvidia's GB300 AI servers. Foxconn acquired the Lordstown plant, previously a General Motors small-car factory, in 2022 for $230m from the now-bankrupt US electric vehicle startup Lordstown Motors Corp, as part of its strategy to expand into the electric vehicle sector. In 2022, the company began pre-production at the Lordstown Motors plant and had initially invested in the facility to produce electric pickup trucks in collaboration with Lordstown. However, the partnership deteriorated, leading to Lordstown Motors' bankruptcy and subsequent legal action against Foxconn. In its announcement, Foxconn stated that it sold the factory to an "existing business partner," but did not provide additional information. The company reaffirmed its commitment to automotive customers in the US, indicating its capability to quickly scale up automotive production to meet demand when necessary. Foxconn's recent activities reflect its ongoing expansion beyond its traditional role as an iPhone assembler. Last week, the company announced a strategic partnership with industrial motor manufacturer TECO Electric & Machinery to develop data centres. In June 2025, Elektrobit signed a joint development agreement with Foxconn to create a new AI-centric software platform intended to support software-defined electric vehicles. "Foxconn to sell former car factory in Ohio for $375m" was originally created and published by Just Auto, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
an hour ago
- Yahoo
Gynecological Devices Market Valuation to Reach US$ 20.19 Billion By 2033
Driven by an aging population and a strong shift toward minimally invasive procedures, the market is dominated by surgical devices and robotics. Hospitals and clinics remain primary end-users, investing heavily in advanced technology despite reimbursement pressures. Chicago, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The global gynecological devices market was valued at US$ 10.18 billion in 2024 and is expected to reach US$ 20.19 billion by 2033, growing at a CAGR of 7.90% during the forecast period 2025–2033. The global gynecological devices market is currently navigating a period of profound and accelerated transformation. This is not a gradual evolution but a dynamic surge, creating a landscape rich with opportunity for manufacturers, investors, and healthcare systems worldwide. A confluence of powerful drivers—including an unprecedented influx of venture capital into women's health technology, the escalating prevalence of complex gynecological conditions, and a wave of disruptive technological advancements—is fueling this robust growth. The market is moving beyond incremental improvements toward fundamental shifts in diagnostics and therapeutics. Free Report Sample Available for Immediate Download: An exhaustive analysis of data reveals a compelling, multi-layered narrative of expansion. This in-depth market research report dissects nine critical segments, presenting meticulously researched, data-driven insights that collectively illuminate the immense and multifaceted opportunities materializing across the global gynecological devices market. Key Finding in Gynecological Devices Market Market Forecast (2033) US$ 20.19 billion CAGR 7.90% Largest Region (2024) North America (42%) By Product Surgical Devices (53.0%) By End Users Hospitals & Clinics (65.26%) Top Drivers Rapidly aging female population creates a growing patient base. Government initiatives are increasingly focused on promoting women's health. High adoption of advanced and innovative medical technologies. Top Trends Rising physician preference for minimally invasive surgical techniques. Growing use of robotic-assisted surgery for gynecological procedures. Increased focus on early diagnostics with advanced imaging systems. Top Challenges Strict and lengthy regulatory approval cycles for new devices. Declining national birth rate impacting obstetrics device demand. Stringent reimbursement policies and pressure on healthcare cost containment. Venture Capital Investment Ignites a Firestorm of Femtech and Gynecological Device Innovation The financial landscape for women's health has been transformed by a massive surge of venture capital, directly spurring innovation and growth in the gynecological devices market. Funding for femtech startups has exceeded US$5 billion since 2020, with US$1.2 billion deployed in 2024 alone. Broadening the view to all women's health startups brings the 2024 total to US$2.6 billion, and, including all women-centric conditions, investment in the US and Europe reached nearly US$10.6 billion in 2024. This is a truly global trend. In Europe, €339.4 million was invested across 47 femtech deals in 2024, and European femtechs had already attracted over €334 million in venture capital by March 2025. This capital empowers companies to launch breakthrough products, fueling a new wave of innovation. Recent examples include Future Family securing a US$400 million financing program in April 2025 and ByHeart raising US$72 million the same month for manufacturing expansion. Significant 2025 investments underscore the diversity of innovation: Gesynta Pharma (US$29 million) and Conceivable Life Sciences (US$18 million) are advancing novel treatments, while Delfina (US$17 million), Twentyeight Health (US$10 million), and Teal Health (US$10 million) highlight the growing impact of AI-powered maternal health and accessible care. The funding cascade continues with Kegg (US$6.5 million), Egal (US$4 million), Fizimed (€4 million), Ema (US$3 million), Trellis Health (US$1.8 million), Raaz (US$1 million), Calla Lily (£1 million), Mabel (€600,000), Femble (€350,000), and AuraFem Health (US$200,000). The UNICEF Venture Fund further nurtures innovation, offering up to US$100,000 in equity-free funding for emerging economies, ensuring support at every level. Addressing Uterine Fibroids Creates a Significant and Highly Costly Market Opportunity Uterine fibroids represent a highly prevalent and economically significant condition, creating a vast and sustained demand for effective therapeutic solutions within the gynecological devices market. The sheer scale of this public health issue is immense. As of 2024, the estimated annual economic cost of uterine fibroids in the United States has escalated to an astonishing US$41.4 billion. A major component of this economic burden is productivity loss, with an estimated US$17.2 billion lost annually in the U.S. due to missed work and short-term disability. The patient population itself is expanding, with data showing that the number of women in the U.S. diagnosed with uterine fibroids increased by 10.6% between 2010 and 2022. This steady growth signals a consistently expanding patient base requiring treatment. The high out-of-pocket cost of traditional surgical interventions further amplifies the market need for innovative, less invasive, and more cost-effective devices. Without insurance coverage, a myomectomy procedure can cost between US$11,000 and US$22,000, while a full hysterectomy ranges from US$9,600 to US$24,000. Alternative, device-centric treatments also carry substantial price tags, with uterine artery embolization costing between US$10,000 and US$15,000, and radiofrequency ablation ranging from US$8,900 to US$20,000. These costs exhibit significant geographic variability; for instance, a laparoscopic hysterectomy could cost approximately US$28,000 in Cleveland, Ohio, while the same procedure in Atlanta, Georgia, might be closer to US$19,000. This cost-prohibitive environment creates a powerful incentive for the adoption of new technologies in the gynecological devices market that can offer superior outcomes at a lower total cost of care. Assisted Reproductive Technology Forges a Burgeoning and Profitable Niche Device Market The increasing societal demand for fertility assistance, driven by trends such as delayed parenthood and rising infertility rates, is a potent force shaping a specialized and highly profitable segment of the gynecological devices market. The global demand for these services is immense, with approximately 2.5 million In-Vitro Fertilization (IVF) cycles now being performed annually across the world. This trend is particularly pronounced in the United States, where the number of IVF cycles performed in SART (Society for Assisted Reproductive Technology) member clinics surged from 389,993 in 2022 to 432,641 in 2023. These procedures directly resulted in the birth of 95,860 babies in the U.S. in 2023. Comprehensive data from 2021 shows that 238,126 patients in the U.S. initiated a total of 413,776 ART cycles, demonstrating the high volume of procedures. The financial investment from patients is substantial and directly fuels demand for the sophisticated equipment, consumables, and diagnostic tools used in these delicate procedures. The average cost of a single IVF cycle in the U.S. ranges from US$12,000 to US$17,000, with some reports from the Department of Health and Human Services placing the potential cost between US$15,000 and US$20,000. This sustained, high-value patient expenditure ensures a robust and growing revenue stream for manufacturers of the specialized instruments essential to modern fertility treatment, making it a cornerstone of the modern gynecological devices market. Robotic Surgery Revolutionizes Gynecological Procedures and Propels Advanced System Device Adoption Minimally invasive robotic surgery has become the gold standard for many gynecological procedures, offering greater precision, shorter recovery times, and improved patient outcomes. This shift is driving rapid adoption of advanced robotic surgical systems, with the da Vinci system leading the market. In 2024 alone, 2,683,000 procedures were performed globally using da Vinci systems, reflecting exponential usage growth. Hardware sales surged as well, with 493 da Vinci surgical systems placed in healthcare facilities in Q4 2024, bringing full-year placements to 1,526. This expansion resulted in substantial financial gains: Intuitive Surgical reported US$2.41 billion in revenue for Q4 2024, up 25% from the previous year. Recurring revenue in the gynecological devices market from proprietary instruments and accessories climbed to US$1.41 billion in Q4, while capital sales of the systems hit US$1.97 billion for the full year. The da Vinci system generally sells for US$0.7 million to US$3.1 million, signifying significant capital commitment from hospitals. By 2020, over 5,500 da Vinci systems were installed in U.S. hospitals, with more than 2,000 hospitals nationwide now utilizing robotic surgery systems. This robust infrastructure supports continued growth: the global gynecological surgery robot market reached approximately US$3.2 billion in 2024 and is poised for further expansion. The outlook is especially strong given that nearly 600,000 hysterectomies are performed in the U.S. every year, many ideal for robotic assistance. Rising Prevalence of Pelvic and Endometrial Disorders Spurs Urgent Device Innovation A growing awareness among both patients and clinicians regarding the diagnosis and treatment of widespread yet historically underdiagnosed conditions such as endometriosis and pelvic organ prolapse (POP) is opening new frontiers for the gynecological devices market. The addressable patient population is substantial and expanding. Projections indicate that the number of American women suffering from at least one pelvic floor disorder is set to increase to 43.8 million by the year 2050. More specifically, the number of women with POP in the U.S. is expected to climb to 4.9 million by 2050, while the global population of POP patients is projected to reach an enormous 156 million by 2036. For endometriosis, a condition infamous for its diagnostic challenges, the average time from symptom onset to a definitive diagnosis is currently a staggering 8 years and 10 months. This diagnostic delay represents a critical unmet need and a clear opportunity for innovative diagnostic devices. Promising clinical research is underway to address these therapeutic gaps. A clinical trial involving 36 participants is evaluating a cannabidiol extract for endometriosis pain and is expected to conclude in December 2024, while another larger pain reduction trial with 102 participants is set to conclude in August 2024. Success in these trials could pave the way for new treatment paradigms supported by new devices. At-Home Testing Empowers Consumers and Rapidly Expands the Diagnostic Device Market A fundamental paradigm shift toward patient-centric care, emphasizing convenience, privacy, and empowerment, is fueling explosive growth in the at-home testing sector. This consumer-driven movement represents a critical expansion corridor for the diagnostic segment of the gynecological devices market. The market size reflects this rapid adoption; the global at-home testing market is estimated to reach a value of US$7,789.1 million in 2025, a healthy increase from its US$7,432.3 million valuation in 2024. The fertility testing sub-market is a particularly strong contributor to this growth, and it is estimated to be valued at US$672.9 million in 2025. Long-term projections are even more bullish, with the global Ovulation Test Market projected to expand to US$4.04 billion by 2032. Similarly, the broader global Fertility Testing Devices Market, which was valued at US$702.59 million in 2023, is projected to surge to an impressive US$1,171.55 million by 2032. The distribution channels for these devices are also modernizing to meet consumer demand. The online pharmacy segment has emerged as the dominant channel, holding the largest share of the fertility testing devices market in 2023 at 41.12%. This trend opens up a powerful direct-to-consumer channel, reshaping marketing and logistics for the entire gynecological devices market. Core Surgical and Diagnostic Device Advancements Enhance Overall Patient Care Efficacy Relentless and continuous innovation in the design and function of core surgical and diagnostic instruments remains a fundamental pillar of growth for the gynecological devices market. These advancements directly translate into improved clinical efficacy, enhanced safety profiles, and better patient experiences. A landmark development occurred in 2025 when Kephera Diagnostics launched its EndomTest, which stands as the first commercially available non-invasive blood test for endometriosis in the United States. This represents a significant leap forward in diagnostics. Simultaneously, the regulatory environment is adapting to support and safeguard this innovation. In November 2024, the Food and Drug Administration (FDA) announced a new communications pilot program specifically designed to enhance the medical device recall process, a program that explicitly includes obstetrics and gynecology devices. This heightened focus on safety is critical, as evidenced by an April 2024 recall of Boston Scientific's Obsidio Embolic device. A comprehensive review of high-risk recalls from 2002 through 2016 identified 7 distinct class I recall events that affected over 88,000 women's health medical devices. This history informs the current proactive regulatory stance, which ultimately fosters greater trust and ensures the long-term, sustainable health of the gynecological devices market. Tailor This Report to Your Specific Business Needs: The Staggering Economic Burden of Gynecological Conditions Underscores Urgent Device Need The immense economic weight imposed by common gynecological conditions on healthcare systems, employers, and patients provides a powerful and persuasive argument for the value proposition of effective and cost-efficient medical devices. The annual economic burden of uterine fibroids in the U.S. is a clear example, estimated to be as high as US$41.4 billion. A major driver of this staggering cost is the impact on workforce productivity, with lost wages due to fibroids costing American women approximately US$17.2 billion every year. The economic drain extends beyond fibroids. The annual surgical costs in the U.S. for treating pelvic organ prolapse now exceed US$1.523 billion. These multi-billion-dollar figures create a compelling business case for payers and healthcare providers to aggressively invest in advanced gynecological devices. Devices that can reduce the need for expensive surgeries, shorten hospital stays, minimize recovery times, and mitigate long-term complications offer a clear and quantifiable return on investment. This powerful economic reality serves as a persistent and significant demand driver for the entire gynecological devices market. Global Gynecological Devices Market Major Players: Karl Storz SE & Co. KG Hologic Inc. Boston Scientific Corporation B. Braun Melsungen AG Becton, Dickinson and Company CONMED Corporation CooperSurgical Inc. Coloplast A/S Johnson & Johnson (Ethicon) Medtronic plc Olympus Corporation Stryker Corporation Richard Wolf GmbH Intuitive Surgical Teleflex Incorporated Minerva Surgical Inc. Lumenis Ltd. Other Prominent Players Market Segmentation: By Product Surgical Devices Gynecological Imaging Devices Portable Tools By End Use Hospital & Clinics Ambulatory Surgery Centers (ASCs) By Region North America Europe Asia Pacific Middle East Africa South America Explore the Report Before You Buy – Book a Walkthrough: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website:
